苏金单抗对银屑病关节炎滑膜炎的Power Doppler超声应答:III期ULTIMATE研究12周结果
ULTIMATE是一项随机、安慰剂对照III期研究,纳入166例对传统DMARDs应答不足且未使用生物制剂的活動性PsA患者,比较苏金单抗与安慰剂对超声滑膜炎的改善。12周时苏金单抗组GLOESS改善显著优于安慰剂,差异为-3(95%CI -6至-1),且最早在治疗1周后即显现。所有关键次要终点均达到,未发现新的安全性信号。
要点
- 苏金单抗12周时GLOESS较基线的校正均值变化优于安慰剂,差异有统计学意义。
- GLOESS在苏金单抗与安慰剂间的差异最早在治疗开始后1周即显著。
- 所有关键次要终点(包括ACR 20和50应答)均达到,未报告新的安全性发现。
核心结论
- 苏金单抗抑制IL-17A可快速且显著降低银屑病关节炎患者的超声滑膜炎,同时改善PsA的症状和体征。
研究设计与样本
- 随机、安慰剂对照、III期ULTIMATE研究纳入166例活动性PsA患者,这些患者有活动性超声滑膜炎和临床滑膜炎及附着点炎,对传统DMARDs应答不足且未使用过生物制剂。
- 患者随机接受每周皮下苏金单抗(根据银屑病严重程度为300 mg或150 mg)或安慰剂,此后改为每4周给药。
- 主要终点为第12周超声GLOESS较基线的平均变化,关键次要终点包括ACR 20和50应答。
主要发现
- 166例入组患者中97%完成12周治疗(苏金单抗组99%,安慰剂组95%)。
- 第12周时苏金单抗组GLOESS校正均值变化为-9(0.9),安慰剂组为-6(0.9),差异(95%CI)为-3(-6,-1),单侧P=0.004。
- 苏金单抗与安慰剂间GLOESS差异最早在治疗开始后1周即显著。
- 所有关键次要终点均达到,未报告新的或非预期的安全性发现。
关键数值与推荐
- 主要终点:第12周GLOESS较基线变化,苏金单抗组-9(0.9) vs 安慰剂组-6(0.9),差异(95%CI)-3(-6,-1),单侧P=0.004。
- 关键次要终点包括ACR 20和50应答,所有关键次要终点均达到。
临床怎么用
- 对于对传统DMARDs应答不足且未使用生物制剂的活動性PsA伴超声滑膜炎患者,苏金单抗可在1周内快速改善滑膜炎。
- 苏金单抗在改善PsA症状和体征的同时,可显著降低超声滑膜炎,支持其用于PsA的滑膜炎控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active PsA using Power Doppler ultrasound. METHODS: The randomized, placebo-controlled, Phase III ULTIMATE study enrolled PsA patients with active ultrasound synovitis and clinical synovitis and enthesitis having an inadequate response to conventional DMARDs and naïve to biologic DMARDs. Patients were randomly assigned to receive either weekly subcutaneous secukinumab (300 or 150 mg according to the severity of psoriasis) or placebo followed by 4-weekly dosing thereafter. The primary outcome was the mean change in the ultrasound Global EULAR and OMERACT Synovitis Score (GLOESS) from baseline to week 12. Key secondary endpoints included ACR 20 and 50 responses. RESULTS: Of the 166 patients enrolled, 97% completed 12 weeks of treatment (secukinumab, 99%; placebo, 95%). The primary end point was met, and the adjusted mean change in GLOESS was higher with secukinumab than placebo [-9 (0.9) vs -6 (0.9), difference (95% CI): -3 (-6, -1); one-sided P=0.004] at week 12. The difference in GLOESS between secukinumab and placebo was significant as early as one week after initiation of treatment. All key secondary endpoints were met. No new or unexpected safety findings were reported. CONCLUSION: This unique ultrasound study shows that apart from improving the signs and symptoms of PsA, IL-17A inhibition with secukinumab leads to a rapid and significant reduction of synovitis in PsA patients. TRIAL REGISTRATION: ClinicalTrials.gov; NCT02662985.
引用
- D'Agostino MA, Schett G, López-Rdz A, et al. Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Rheumatology (Oxford). 2022. PMID: 34528079. doi:10.1093/rheumatology/keab628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。